Total Health 2023
Channels: Patients and MedicalEvent Date: Tue, 2023-11-07 toWed, 2023-11-08Event URL: https://bit.ly/43a1rQaEvent Location: History: Number of attendees: 150Programme URL: Brochure URL: Speakers URL: Purchase Recording URL: Event Organiser: Eleni PapaspyrouEvent Organiser E-mail: Eleni.Papaspyrou@thomsonreuters.comPr écis: Dive into the new era of healthcareEntire Month Duration: NoEvent Image: Audiences: Health ProvidersPayersHealth TechPolicy MakersPharma (Source: EyeForPharma)
Source: EyeForPharma - July 17, 2023 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
Pharma should embrace its role as a trusted information source
Industry Experts Who Contributed: All contributors are senior leaders within the pharmaceutical industry Scott Bradley, VP, Patient and Specialty Services Strategy and Deliver,Novartis Laurie Hughes, VP, Patient Services,Biogen Nneka Nwokolo, Global Lead of Patient Affairs,ViiV Healthcare Dora Elena Arias, Founder and Executive Director,Cur émonos Moderator: Jennifer Turcotte, Senior Director, Pharma Strategy,Salesforce Watch the Full WebinarHere. Actionable Insights: Patients are increasingly doing their own health research: To help combat disinformation and maintain public trust in the he...
Source: EyeForPharma - July 11, 2023 Category: Pharmaceuticals Authors: Maria Aguirre Galindo Source Type: news
Optimize next best action tools to deliver value-based engagement
This article will dive deep into what our webinar expert speakers believe to be key aspects to accomplish a true omnichannel engagement offering, with a focus on personalised, next-best action engagement (NBA). The speakers currently focus on implementing tools in their companies to drive omnichannel strategy, and the insights gathered from the discussion are shared in the form of a 6-stage roadmap to facilitate understanding of what to consider.To understand the challenges the industry is facing to accomplish an orchestrated engagement approach, we asked webinar attendees to select the challenges that concerned them the m...
Source: EyeForPharma - June 23, 2023 Category: Pharmaceuticals Authors: Maria Aguirre Galindo Source Type: news
Optimize Next Best Action Tools to Deliver Value-based Engagement, facilitated by IQVIA
This article will dive deep into what our webinar expert speakers believe to be key aspects to accomplish a true omnichannel engagement offering, with a focus on personalised, next-best action engagement (NBA). The speakers currently focus on implementing tools in their companies to drive omnichannel strategy, and the insights gathered from the discussion are shared in the form of a 6-stage roadmap to facilitate understanding of what to consider.To understand the challenges the industry is facing to accomplish an orchestrated engagement approach, we asked webinar attendees to select the challenges that concerned them the m...
Source: EyeForPharma - June 23, 2023 Category: Pharmaceuticals Authors: Maria Aguirre Galindo Source Type: news
Optimize Next Best Action Tools to Deliver Value-based Engagement, facilitated by IQVIA.
This article will dive deep into what our webinar expert speakers believe to be key aspects to accomplish a true omnichannel engagement offering, with a focus on personalised, next-best action engagement (NBA). The speakers currently focus on implementing tools in their companies to drive omnichannel strategy, and the insights gathered from the discussion are shared in the form of a 6-stage roadmap to facilitate understanding of what to consider.To understand the challenges the industry is facing to accomplish an orchestrated engagement approach, we asked webinar attendees to select the challenges that concerned them the m...
Source: EyeForPharma - June 23, 2023 Category: Pharmaceuticals Authors: Maria Aguirre Galindo Source Type: news
The patient, AI and the search for answers
Just as pharma was beginning to understand and work with the way patients gather healthcare information online, the paradigm is set to change utterly. Thanks so very much ChatGPT.Given the sudden mass global adoption of AI tools powered by large language models, rapid disruption looks certain. The tools, now increasingly on our smartphones, offer highly plausible and personable ways to find convenient answers to the billion health related questions humankind asks daily.AI-generated health advice is out-ranking physicians on both quality and empathy.The allure is clear. AI is proving more empathetic than GPs and it can prov...
Source: EyeForPharma - June 19, 2023 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
PED: Turning the patient voice into a dataset
Get ready to learn a new word: ‘spetspatient’. Coined by Dr. Sara Riggare, a patient researcher in health informatics with the Participatory eHealth& Health Data Research Group at Uppsala University, roughly translated it means ‘lead patient’. It ’s a term we may want to get used to as the industry comes to see the value, and increasingly the imperative, of reliably capturing what it’s like for patients to experience a condition, to live with it day to day and to treat it.There is a growing recognition of the value of using the patient voice as a dataset in this way, says Riggare. “I see the start of a n...
Source: EyeForPharma - April 3, 2023 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Making strategic sense of pharma ’s new race for competitive advantage
Cheaper, faster R&D matters hugely of course, but it is increasingly the case that commercial success will only follow if pharma can also deliver for patients and health systems. Patients are increasingly active participants in their own care. They are becoming intolerant of high-friction, low-quality provision of care. Resource constrained health systems, meanwhile, urgently require partners able to help them do more with less. Advantage in the life sciences, then, will increasingly go to those that can develop new products, services and digital ecosystems to make the most of this new competitive landscape. When...
Source: EyeForPharma - March 16, 2023 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Love and sacrifice: The Zena Sfeir Story
It ’s funny how no one thinks they have a story worth listening to. That’s what Zena Sfeir, Aitia (formerly GNS) VP Marketing, said as we embarked on her interview. My eyes widened as her story slowly unfolded. Talk about resilience. When you combine that resilience with a huge capacity for love and a mindset of service, the sky is the limit. Zena ’s journey is proof. Zena was born and raised in Beirut towards the end of the Lebanese Civil War. So, in a way, the war felt ‘normal’ to her. Looking back decades later, she says she still remembers it as a happy childhood, despite the conflict. While her family hid ...
Source: EyeForPharma - March 16, 2023 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Wired for success in omnichannel
The mastery of omnichannel requires many parts of every pharma business to align and co-operate but perhaps one of the most important, but underemphasized partnerships is that between marketing communications (marcomms) and IT colleagues. Only together can they develop the right tools, including platforms, data analytics, automation, and artificial intelligence (AI), to do the job effectively. IT ’s expertise on a range of issues including hardware and software compatibility, budgets, data security, and training and support issues, make closer working relationships with it essential, says Craig McGettigan, Head of Om...
Source: EyeForPharma - March 13, 2023 Category: Pharmaceuticals Authors: Joseph Constance Source Type: news
Getting ready for primetime in cell & gene therapy
Cell and gene therapies (CGTs) have a lot going for them from an industry perspective – with a market predicted to reach US$50 billion annually by 2027, an opportunity to expand the frontier of medical science and the potential to save or improve countless lives. But with logistical, supply chain and manufacturing complexities interwoven into development, bringing CGTs to large patient populations may prove uniquely challenging.With over 3,633 therapies in development as of mid-2022, CGTs are two of the fastest-growing areas of healthcare. To date, less than two dozen therapies have made it to market, but this numbe...
Source: EyeForPharma - December 8, 2022 Category: Pharmaceuticals Authors: Clare Jackson Source Type: news
Building a commercial dream team for today ’s pharma industry
Nearly three years since COVID-19 abruptly forced pharmaceutical commercialization teams to adopt fully digital engagement models, the industry has adjusted to a more complex and diverse mix of engagement modalities.Pharma is adapting to this hybrid engagement model along with a host of other changes to engagement strategies by rethinking the makeup of commercialization teams and the skills that they prioritize.In many ways the rep ’s role has become more complex. There is a growing requirement for them to connect the right decision-makers at the provider with the right subject matter experts in pharma. In addition, flex...
Source: EyeForPharma - December 7, 2022 Category: Pharmaceuticals Authors: Brian Eastwood Source Type: news
Building a commercialization dream team for today ’s pharma industry
Nearly three years since COVID-19 abruptly forced pharmaceutical commercialization teams to adopt fully digital engagement models, the industry has adjusted to a more complex and diverse mix of engagement modalities.Pharma is adapting to this hybrid engagement model along with a host of other changes to engagement strategies by rethinking the makeup of commercialization teams and the skills that they prioritize.In many ways the rep ’s role has become more complex. There is a growing requirement for them to connect the right decision-makers at the provider with the right subject matter experts in pharma. In addition, flex...
Source: EyeForPharma - December 7, 2022 Category: Pharmaceuticals Authors: Brian Eastwood Source Type: news
Scaling CGT through automation
Cell and gene therapies need to be made cheaper. Much cheaper. With price tags in the millions, they will never be able to deliver on their promise of personalized cures at scale.It will take time for the industry to take costs below $1m per dose from the typical current price in the $2m-3m range. And even this reduction is nowhere near enough to reach patient populations beyond the richest countries and health systems. More automated manufacturing offers one of the most significant ways to cut costs. The sector has been moving hospital lab manufacture towards more standardised and repeatable processes in dedicated facil...
Source: EyeForPharma - November 22, 2022 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Advancing health equity for the LGBTQIA+ community
Healthcare systems are failing the LGBTQIA+ community and transgender individuals in particular. Too often they are not getting the care they need.
The stigma and discrimination of recent decades die hard and continue to negatively impact LGBTQIA+ healthcare outcomes in many cases. New approaches and new attitudes to delivering healthcare, without discrimination, are needed to ensure that this community thrives. A key challenge facing LGBTQIA+ patients is varying attitudes to the community in different parts of the world and even in different states or regions. Increased health risksOne important dimension of he...
Source: EyeForPharma - November 9, 2022 Category: Pharmaceuticals Authors: Katie Delaney Source Type: news
